Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics
Scott A McConnell,1 Dharmik N Desai,1 Sejal P Faldu,1 Marjie L Hard,2 Angela Y Wehr,3 Peter J Weiden,1 Lisa von Moltke3 1Medical Affairs, Alkermes, Inc., Waltham, MA, 2Nuventra Pharma Sciences, Durham, NC, 3Clinical Research, Alkermes, Inc., Waltham, MA, USAThe recent publication by Salzman et al1...
Saved in:
Main Authors: | McConnell SA, Desai DN, Faldu SP, Hard ML, Wehr AY, Weiden PJ, von Moltke L |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/8036fa34f015403b9c1b841a7c733a17 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
by: Citrome L, et al.
Published: (2019) -
Aripiprazole en el tratamiento sintomático del síndrome de Gilíes de la Tourette (enfermedad de los tics)
by: Miranda C,Marcelo, et al.
Published: (2007) -
Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
by: Chih-Sung Liang, et al.
Published: (2021) -
Aripiprazole for late-life schizophrenia
by: Jeffrey Rado, et al.
Published: (2010) -
DEVELOPMENT OF A SIMPLE AND SPECIFIC UHPLC ASSAY FOR THE DETERMINATION OF ARIPIPRAZOLE AND DEHYDROARDPDPRAZOLE IN RAT PLASMA
by: YENICELI UĞUR,DUYGU, et al.
Published: (2015)